China has several hospitals where treatment of liver cancer can be?
This year my brother was 20 years old, the end of last year found that liver. We do not know which countries have several hospitals have a precedent for treatment of liver cancer! ! Well-intentioned people would like to have given me a little guidance! !
Answer:
First, your brother had liver cancer sorry performance.
Hepatocellular carcinoma (HCC) is seriously endangering the health of human life and serious diseases, the global number of new 55 percent suffering from liver cancer occurred in China, China's average standard of male liver cancer mortality rate was 14.52/10 million 5.61/10 million women across the country Each year, about 100,000 people die of liver cancer. The incidence of occult liver cancer, clinical only less than 30% of patients available to Hepatectomy represented opportunities for surgical treatment, while patients with liver cancer recurrence after surgery a high rate of patients after treatment of tumor recurrence is also relatively more difficulties. Since the diagnosis in patients with liver cancer after an average of 6 months the survival rate of less than 50%, 5-year survival rate of only 5%.
But now can prolong life����͡, conditions permitting, can also look for opportunities for further treatment!
Fourth Military Medical University successfully developed liver targeted drug
December 17, 2007 17:25:49 Source: Xinhua
Xi'an Xinhua December 17 (Xinhua XU Zu-hua, Ding Haitao) reporter on the 17th that from the Fourth Military Medical University, the school successfully developed a special autonomy for the treatment of liver cancer-specific antibody-targeted drugs - Iodine [131 ��] U.S. Rituximab Injection (����͡).
The drug from the Fourth Military Medical University, director of the Center for Cell Engineering Research Professor Chen Zhinan rate group formed after 20 years of development. According to clinical experts, the first time solved the����͡
Fragment antibody preparation technology, targeting vector easy to penetrate into the cancer tissue, but also solved the antibody immune response caused by the defects. Can be used as the period of the first-line treatment of liver cancer drugs or radiotherapy, chemotherapy drugs combined.
According to the annual health report of the World Health Organization, the world each year 620,000 people die of liver cancer.
<a href="http://news.xinhuanet.com/newscenter/2007-12/17/content_7268261.htm" target="_blank"> http://news.xinhuanet.com/newscenter/2007-12/17 / content_7268261.htm </ a>
Title of the article after intervention of liver cancer
Content doctors, Hello! My father found that up to now has done a 3 times better involved in tumor control, AFP declined from 1000 to the present 9. Liver function better, and now ALT is 58, AST51, bilirubin and protein are normal. is GGT288, ALP180 a bit high, but also look a bit dark, a bit large pores, as if the liver detoxification function work? Is there any way to reduce GGT and ALP it? improve face? Thank you,
Reply to the views of Hello, because of liver cancer outside group of experts to participate in academic conferences, and now only respond to your information, so sorry. I do not know whether you do in our hospital����͡and, if so, can this name, we are your father's medical records could be released, according to the actual situation is more to answer you, could you?
Time published counseling released 2008-3-14
Transfer from the People's Liberation Army medical�������———- (in Guangdong) website <a href="http://www.458hepatology.com/index.asp" target="_blank"> http://www.458hepatology.com/index.asp </ a>
Unfortunately, I have a cousin in Canton did not use the work on����͡, in June last year, has been mercilessly took the lives of liver cancer, so his family and our people very sad, because he is still a medium The officer, is our pride. According to the information in your house, in your house to use the first����͡patients should be more than six months, may I ask how their current condition? They also have many people to survive? The ratio of the number of survival? Whether it was the second injection needles? I hope you will as soon as possible to the true effect����͡looking forward to tell the patients! Thanks!
Reply to the views of Hello, under normal circumstances of patients diagnosed with liver cancer, the average survival time was 4.2 months, after the use of����͡median survival time of patients in which more than 19 months. Center����͡I have spent more than 80 cases of treatment of liver cancer patients, there are more than 60 percent efficiency. 1-6 can����͡injection needles Up to now, I Center injected more than ten people have been No. 2 needles, 5 patients injected with No. 3 pin.����͡with traditional chemotherapeutic agents as compared to virtually no side effects, occasional one-off of low-grade fever, skin rashes and so on. Safety.
Released were released jyx time 2008-3-4
Transfer from the People's Liberation Army medical�������———- (in Guangdong) website <a href="http://www.458hepatology.com/index.asp" target="_blank"> http://www.458hepatology.com/index.asp </ a>
The world's first treatment of primary liver cancer monoclonal antibody drug-oriented, but also with all the intellectual property of antibody drugs -����͡
One double-effect: the United States closed Rituximab hepatoma cells inhibited the proliferation of antigen Hab18G/CD147 transfer
Iodine [131I] ��-ray fired to kill liver cancer cells
—————- Transfer from Chengdu Hua God Biotechnology Co., Ltd.
Efficacy than expected
. According to our research to understand the company in 2007 sold a small amount of����͡products (over 100-pin) are basic
Liver cancer patients tried all the methods of the invalid, after the use of despair, and so far, its effect super -
Expected, some hospitals in the use of the process also found on cancer cells����͡transfer effect especially.
.����͡an R & D and Clinical is the fourth largest military doctors completed, II and III clinical is������
Completed 2 years when more than 103 cases of clinical cases.����͡that have been carried out from the clinical trial results showed that
103 cases of primary liver cancer in patients with two cycles (2����͡) treatment, a significant improvement in symptoms.
Chart 1����͡clinical data
Clinical remission rate (CR + PR) 8.22%
The clinical efficacy (CR + PR + MR) 27.40%
Clinical control rate (CR + PR + MR + SD) 86.30%
Median survival time 19 months
18-month survival rate of 51.98%
Private Investigation Report
Application of radionuclide targeted drug intervention in the treatment of liver cancer
Shandong Dong hearing recently, Shandong Provincial Hospital digestive medicine Professor Zhang Chunqing, Jun-Yong Zhang, an associate professor in Professor Liu Chunyu, director of Nuclear Medicine for their assistance, the successful implementation of a case of advanced liver cancer patients with liver cancer "guided bombs" in the treatment, made significant effect.
Accept the intervention of minimally invasive surgery patient is a middle-aged men, two months ago, right upper quadrant digestive medicine does not come to the hospital for treatment, the diagnosis for giant liver cancer, tumor diameter of about 10 centimeters, and with There are the portal vein and abdominal lymph node metastasis, liver cancer tumors in patients with an advanced, there are no opportunities for surgical excision. After diagnosis, the Group has given the traditional interventional treatment, CT examination showed that there is still some residual tumor. Expert Group to consider is the intervention of liver cancer recurrence after repeated multidisciplinary consultation, decided to adopt the radionuclide targeting interventional therapy drugs. Surgery by Professor Zhang Chunqing and Jun-Yong Zhang, associate professor of implementation. After the surgery, in patients with inguinal Department about 0.5 centimeters to make a small incision, the catheter to the blood vessels supplying liver cancer and will be followed by liver cancer marker specific antibody 131I radioisotope injection through the catheter to the tumor tissue, thus the specificity and anti-hepatoma cells. Intervention operation goes smoothly, patients recovered well. Discharged from hospital 15 days later review of ECT, showed that patients with liver still isotope drug deposition, the effect of interventional treatment significantly, in patients with abdominal pain, bloating adverse symptoms, quality of life and the general situation of a good recovery.
According to Professor Zhang Chunqing, the so-called "guided bombs" in the treatment, it is the application of the treatment of primary liver cancer radionuclide intervention targeted drug treatment, the use of targeted drug and liver cancer cells characterized by high affinity will have a choice 131I Strip of the tumor tissue, 131I release of high-energy ��-ray close-up, long time anti-tumor cells, rather than normal tissue injury. After using the methods of treatment, drugs specifically deposited in tumor tissue, the body of other devices without the accumulation of radioactive substances, compared with the traditional side effects of chemotherapy. Nuclide targeted drug clinical application, fill the interventional treatment of liver cancer in Shandong Province another blank.
Professor Zhang Chunqing stressed that as a result of liver cancer occult, once found surgery often have lost the opportunity, so surgical resection rate of liver cancer less than 15 percent, and the presence of high postoperative recurrence, high-transfer and other issues. For patients who can not be surgically removed, commonly used in clinical treatment methods for intervention chemoembolization that in liver blood vessels supplying the local injection of chemotherapy drugs and embolization of liver cancer blood vessels, so as to achieve the purpose of killing cancer cells. However, its overall effect for the poor, side effects. At present, advanced liver cancer was only natural survival time of 3 ~ 6 months. The successful application of this method, the interventional treatment for liver cancer has opened up a new way.
(Gao onwards)
����͡biological-oriented treatment of liver cancer clinical expert consensus
China's Food and Drug Administration (SFDA) in 2006 approved����͡® for the treatment of primary liver cancer, the current domestic drug treatment to meet the increase in accumulated rich experience. For this reason part of liver cancer in China expert at the January 8, 2008 for the treatment of primary liver cancer����͡clinical application guidance summary was discussed for reference.
1. Indication
Clinical trials and application����͡confirm the exact effect of the treatment of primary liver cancer, is safe. Apply to: The clinical, imaging, tumor markers (AFP) and / or pathological examination confirmed no serious liver and kidney dysfunction (Child C, creatinine Cr and blood urea nitrogen BUN), KPS score �� 60 points, occupy the tumor rate <70% of patients with primary hepatocellular carcinoma.
1. For the treatment of the object: meet these standards for all patients with primary hepatocellular carcinoma.
a. small hepatocellular carcinoma: (1) a single tumor, tumor diameter �� 5 cm persons; (2) multiple tumors, the number of <3, the largest tumor diameter �� 3 cm; (3) liver cancer metastasis anhepatic and violations of the great vessels;
b. can not be surgically removed in the late stage of liver cancer, liver and kidney function without serious obstacles, tumor occupied rate <70%;
c. portal vein tumor thrombus, the backbone of some obstruction or complete obstruction, complete obstruction to be proved to have supported the formation of portal circulation;
d. liver cancer surgery (partial resection or liver transplantation) and interventional treatment (TAE / TACE) after the residual cancer;
e. preoperative liver applications, creating opportunities for the second phase operation;
f. liver cancer recurrence after treatment to prevent the disease.
2. Study on the treatment of the object:
a. diffuse hepatocellular carcinoma;
b. lack of blood type of liver cancer;
c. liver cancer liver metastasis by clinical observations,����͡metastasis to the far more obvious symptoms, especially bone metastasis pain, however, prompted ECT extrahepatic metastatic sites with poor concentration, and the effect of differences in contrast .
3. Not suitable for the treatment of the object:
a. Huancavelica͡Ƥtest-positive patients or those who compound iodine solution can not be tolerated;
b. III period of liver cancer, severe liver function impairment (bilirubin> 51��mol / L, serum albumin <30g / L);
c. severe ascites;
d. serious heart, kidney and blood system of patients with diseases;
e. biological agents allergy history of allergy or is in a state of patients with allergies;
f. pregnancy and breast-feeding women.
Application unit
1, Sichuan and Sichuan West China Hospital of Sichuan University Cancer Hospital
2, Shandong and Shandong Provincial Hospital
3, Fujian, the Fujian Provincial Tumor Hospital
4, Hunan People's Hospital of Hunan Province, Hunan Tumor Hospital, Central South University in Hunan Xiangya Second Hospital
5, Zhongshan Hospital of Tongji University in Shanghai and Shanghai subsidiary, Shanghai Tenth People's Hospital
6, Jiangsu Cancer Hospital, Jiangsu Province
7, Xian Hospital of Xi'an Jiaotong University's First Affiliated Hospital of Shaanxi Provincial Tumor Hospital, Fourth Military Medical University
8, Guangdong People's Liberation Army more than 80 medical�������
9, Beijing, China Nuclear Industry 401 Hospital
10, Liaoning, China Medical University Hospital Shengjing
